《Annals Of The Rheumatic Diseases》雜志的最新年發文量為148篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章,以保持其在風濕病學領域的學術影響力。
該刊聚焦于醫學-風濕病學領域的前沿研究,致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 約1.4月 。
Annals Of The Rheumatic Diseases 雜志發文統計
文章名稱引用次數
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus200
- EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice118
- EULAR recommendations for the management of antiphospholipid syndrome in adults109
- 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus98
- 2018 update of the EULAR recommendations for the management of Behcet's syndrome96
- 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis80
- Circular RNA VMA21 protects against intervertebral disc degeneration through targeting miR-200c and X linked inhibitor-of-apoptosis protein54
- Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)51
- Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)51
- Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study51
國家/地區發文量
- USA2085
- England1726
- Spain1493
- Italy1373
- Netherlands1192
- GERMANY (FED REP GER)1174
- France1100
- Japan773
- CHINA MAINLAND709
- Turkey675